MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

NCT01239355 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

NIH

Sponsor class

Stopped Early termination for discouraging results

Conditions

Adult Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Localized Non-Resectable Adult Liver Carcinoma
Recurrent Adult Liver Carcinoma

Interventions

DRUG: Akt Inhibitor MK2206
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)